Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Clinical trials: Trial design in NASH--realities and challenges.

Angulo P.

Nat Rev Gastroenterol Hepatol. 2011 Aug 5;8(8):424-5. doi: 10.1038/nrgastro.2011.125. No abstract available.

PMID:
21818144
2.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

3.

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A.

Hepatology. 2011 Jul;54(1):344-53. doi: 10.1002/hep.24376.

4.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
5.

Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease.

Stinton LM, Loomba R.

Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13. Review.

PMID:
24632764
6.

Will non-invasive testing replace liver biopsy in the diagnosis and follow-up of non-alcoholic steatohepatitis (NASH)?

Romero FP.

Rev Esp Enferm Dig. 2009 Aug;101(8):521-7. English, Spanish. No abstract available.

7.

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA.

Gastroenterology. 2011 Jan;140(1):124-31. doi: 10.1053/j.gastro.2010.09.038. Epub 2010 Sep 19.

PMID:
20858492
8.

Pioglitazone trial for NASH: results show promise.

Lang L.

Gastroenterology. 2007 Mar;132(3):836-8. No abstract available.

PMID:
17383411
9.

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Verma S, Jensen D, Hart J, Mohanty SR.

Liver Int. 2013 Oct;33(9):1398-405. doi: 10.1111/liv.12226. Epub 2013 Jun 13.

PMID:
23763360
10.

Pathology and biopsy assessment of non-alcoholic fatty liver disease.

Straub BK, Schirmacher P.

Dig Dis. 2010;28(1):197-202. doi: 10.1159/000282086. Epub 2010 May 7. Review.

PMID:
20460911
11.

Can NASH be diagnosed, graded, and staged noninvasively?

Grandison GA, Angulo P.

Clin Liver Dis. 2012 Aug;16(3):567-85. doi: 10.1016/j.cld.2012.05.001. Epub 2012 Jun 26. Review.

12.

Medical therapy for nonalcoholic fatty liver disease in children and adolescents.

Andrews DB, Lavine JE.

Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):1-3. doi: 10.1586/egh.11.72. No abstract available.

13.

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.

Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL.

Gut. 2010 Jul;59(7):969-74. doi: 10.1136/gut.2009.205088.

PMID:
20581244
14.

Betaine and nonalcoholic steatohepatitis: back to the future?

Mukherjee S.

World J Gastroenterol. 2011 Aug 28;17(32):3663-4. doi: 10.3748/wjg.v17.i32.3663.

15.

Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.

Takahashi Y, Fukusato T.

World J Gastroenterol. 2010 Nov 14;16(42):5280-5.

16.

[Non-alcoholic fatty liver disease--new view].

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, MiezyƄska-Kurtycz J, Milkiewicz P.

Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Review. Polish.

PMID:
18702346
17.

Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men.

Kim JK, Chon NR, Lim HC, Lee KS, Han KH, Chon CY, Park YN, Paik YH.

J Gastroenterol Hepatol. 2012 Jan;27(1):142-8. doi: 10.1111/j.1440-1746.2011.06895.x.

PMID:
21883454
18.

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ.

Hepatology. 2011 Nov;54(5):1610-9. doi: 10.1002/hep.24544. Epub 2011 Aug 24.

20.

Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH).

Schramm C, Schneider A, Marx A, Lohse AW.

Z Gastroenterol. 2008 Dec;46(12):1369-71. doi: 10.1055/s-2008-1027411. Epub 2008 Dec 3.

PMID:
19053005

Supplemental Content

Support Center